Tashiro Hiroki, Takahashi Koichiro, Kurihara Yuki, Sadamatsu Hironori, Kuwahara Yuki, Kimura Shinya, Sueoka-Aragane Naoko
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
J Asthma Allergy. 2022 Feb 9;15:169-177. doi: 10.2147/JAA.S343272. eCollection 2022.
Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare, chronic respiratory disease. Corticosteroid therapy is effective for ICEP, but relapse is frequent after its tapering, which leads to chronic use and corticosteroid-related adverse effects. Currently, biological agents targeting interleukin 5 (IL-5) are considered alternatives for treating ICEP patients with frequent relapse, but the detailed effects are not fully understood.
The clinical characteristics of 30 patients with ICEP, especially 12 patients with ICEP who experienced relapse after corticosteroid dose tapering, were evaluated retrospectively. In addition, 4 ICEP patients with frequent relapse treated by IL-5-targeted biological agents were reviewed.
Of the 30 patients diagnosed with ICEP, 12 patients (40.0%) recurred after corticosteroid dose tapering, and 9 (30.0%) were treated with maintenance doses of corticosteroid. Of ICEP patients who experienced recurrence, 6 (50.0%) had frequent relapses (2 or more times). All 4 patients treated with anti-IL-5 agents had their corticosteroid dose reduced without any relapses; in 3 patients, corticosteroids were withdrawn.
Anti-IL-5 agents might be alternatives for treating ICEP patients with frequent relapses.
特发性慢性嗜酸性粒细胞性肺炎（ICEP）是一种罕见的慢性呼吸系统疾病。皮质类固醇疗法对ICEP有效，但减量后复发频繁，这导致长期使用并产生与皮质类固醇相关的不良反应。目前，针对白细胞介素5（IL-5）的生物制剂被认为是治疗频繁复发的ICEP患者的替代方案，但具体效果尚不完全清楚。
回顾性评估30例ICEP患者的临床特征，特别是12例在皮质类固醇减量后复发的ICEP患者。此外，还对4例接受IL-5靶向生物制剂治疗的频繁复发的ICEP患者进行了回顾。
在30例诊断为ICEP的患者中，12例（40.0%）在皮质类固醇减量后复发，9例（30.0%）接受了皮质类固醇维持剂量治疗。在复发的ICEP患者中，6例（50.0%）频繁复发（2次或更多次）。所有4例接受抗IL-5药物治疗的患者皮质类固醇剂量均减少且无复发；3例患者停用了皮质类固醇。
抗IL-5药物可能是治疗频繁复发的ICEP患者的替代方案。
